Participant flow

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients · Source last updated 2016-07-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   All participants enrolled. Bortezomib: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m\^2 on days 1, 8, 15, and 22 of each 42 day cycle. Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle.

   id

   FG000

   title

   Arm -1 Bortezomib

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         17

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         17

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice